Skip to main content

Table 2 The recipient and donor characteristics of DGF and IGF in the Discovery cohort and the validation cohort

From: Prediction model of delayed graft function based on clinical characteristics combined with serum IL-2 levels

variable

Discovery cohort (n = 71)

Validation cohort (n = 32)

DGF(n = 23)

IGF(n = 48)

p

DGF(n = 12)

IGF(n = 20)

P

Recipient characteristics

Age, yr

39.26 ± 10.767

37.35 ± 11.883

0.517

36.67 ± 13.30

37.65 ± 13.95

0.846

Gender

  

0.904

  

0.854

 Male

15(65.2%)

32(66.7%)

 

7(58.3%)

11(55.0%)

 

 Female

8(34.8%)

16(33.3%)

 

5(41.7%)

9(45.0%)

 

BMI, kg/m2

22.53 ± 5.01

21.49 ± 3.58

0.317

20.38 ± 4.23

20.98 ± 3.20

0.654

Time on dialysis, m

36(24–84)

24(12.5–49.5)

0.110

24(13.75–29.75)

22(12–60)

0.876

Dialysis,HD

16(69.6%)

35(72.9%)

0.506

9(75.0%)

10(50%)

0.289

Immunosuppression regimen

  

0.930

  

0.076

ATG,Tac, MMF, steroid

5(21.7%)

10(20.8%)

 

6(50%)

4(20.0%)

 

Basiliximab,Tac, MMF,steroid

18(78.3%)

38(79.2%)

 

6(50%)

16(80.0%)

 

Pre-Tx Creatinine, mg/dL

12.04 ± 3.53

12.05 ± 3.79

0.988

11.19 ± 3.51

10.93 ± 3.48

0.841

history of hypertension

17(73.9%)

44(91.7%)

0.044

8(66.7%)

16(80.0%)

0.399

history of diabetes mellitus

0(0%)

3(6.3%)

0.221

0(0%)

0(0%)

NA

Donor characteristics

Age, yr

43(35–47)

46(17–49.75)

0.631

38.50 ± 18.76

27.70 ± 15.87

0.092

Gender

  

0.106

  

0.092

 Male

21(91.3%)

36(75.0%)

 

11(91.7%)

13(65.0%)

 

 Female

2(8.7%)

12(25.0%)

 

1(8.3%)

7(35.0%)

 

BMI, kg/m2

23.39(18.37–24.46)

22.49(19.42–24.22)

0.671

24.62(18.53–25.48)

21.35(18.03–24.46)

0.226

Terminal Creatinine, mg/dL

1.52(0.87–4.24)

0.80(0.67–1.08)

0.001

0.37(0.92–1.74)

0.67(0.56–0.80)

0.003

The donor type

  

0.490

  

0.581

 DCD

6(26.1%)

7(14.6%)

 

2(16.7%)

2(10%)

 

 DBD

15(65.2%)

37(77.1%)

 

10(83.3%)

18(90%)

 

 DBCD

2(8.7%)

4(8.3%)

 

NA

NA

 

Donor history of hypertension

15(65.2%)

17(35.4%)

0.018

4(33.3%)

2(10.0%)

0.102

Donor history of diabetes mellitus

10(43.5%)

6(12.5%)

0.003

3(25.0%)

0(0%)

0.019

Transplant characteristics

CIT,h

10.61 ± 2.82

8.36 ± 2.27

0.001

9.5 ± 1.23

7.95 ± 1.34

0.006

HLA mismatches

5(4–6)

5(4–5)

0.663

4(4–5.75)

4.5(4–5)

0.637

  1. Continuous variables were expressed as the mean ± SD or IQR, categorical data were expressed as n%
  2. ATG Anti-thymocyte globulin, Tac Tacrolimus, MMF Mycophenolate Mofetil, Pre-Tx Pre-transplant, HD hemodialysis, CIT Cold ischemia time, HLA Human leukocyte antigen, DCD Donation after cardiac death, DBD Donation after brain death, DBCD Donation after brain death plus cardiac death, BMI Body mass index; NA: Not available
Back to article page

BMC Nephrology

ISSN: 1471-2369

Contact us